Search
Gastric-Cancer-Organoid
Cancer Organoid

Gastric Cancer Organoid

1784€+
Cancer Organoid

Gastric Cancer Organoid

  • Gastric cancer organoids are three-dimensional (3D) models that closely replicate the structure and cellular composition of actual tumor tissue.
  • By preserving key characteristics of gastric cancer, including genetic mutations and protein expression patterns, these organoids serve as reliable models for cancer research.
  • Their ability to maintain tumor heterogeneity and accurately mimic the tumor microenvironment (TME) makes them invaluable for studying disease progression and treatment responses.In particular, organoids derived from the ascitic fluid of patients with advanced gastric cancer reflect the characteristics of metastatic tumors and treatment resistance, playing an important role in evaluating responses to standard therapies and in the development of novel treatment strategies.
  • As physiologically relevant models, these cancer organoids closely mimic the pathological and molecular features of gastric cancer, making them essential tools for studying disease progression, evaluating drug responses, and driving the development of precision medicine-based cancer therapies.

Price
Organism
Human
Product Type
Tissue derived organoid
Tissue
Stomach (Gastric)
Disease
Gastric Cancer, Malignant ascites

Applications

Toxicity

Small molecules

mRNA

Antibody

Cancer vaccine

Immune Cells

Immuno Oncology with TME

Cytotoxic T cell

TIL (Tumor infiltrating lymphocytes)

Regulatory T cell

Macrophage

CAF (Cancer associate fibroblast)

Tomocube (Spatial)
Customer insight

HT-X1: A Label-Free Imaging Breakthrough for Organoid-Based Disease Modeling and Drug Screening

Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...

Seoul National University College of Medicine
Customer insight

Pioneering Spatial Protein Analysis in Korea: Advancing Clinical Pathology with Lambda Biologics’ Support

Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...

K Research Institute
Customer insight

ODISEI-Gut Platform Reveals Immune-Boosting Potential of Kimchi-Derived Bacterial Strain

Among the many fermented foods we consume, kimchi is particularly known for containing a diverse range of lactic acid bacteria, which are believed to influence the activation of immune cells...

Bundang Jesaeng General Hospital
Customer insight

Multiplex Marker Analysis Enhances Research Efficiency with 31-Marker Detection on a Single Slide

We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...

SOON CHUN HYANG UNIVERSITY HOSPITAL
Customer insight

From Limitations to Innovation: Redefining Gastric Cancer Research with Patient-Derived Organoids

Gastric cancer is one of the leading causes of cancer-related mortality worldwide. It is a malignant solid tumor characterized by poor prognosis due to difficulties in early diagnosis and its...

SOON CHUN HYANG UNIVERSITY HOSPITAL
Customer insight

Transforming Gastric Cancer Treatment: Lambda Biologics’ Patient-Derived Organoid Platform

Gastric cancer is one of the leading causes of cancer-related mortality worldwide. It is a malignant solid tumor characterized by poor prognosis due to difficulties in early diagnosis and its...

Description

Cellular and structural similarity

Our gastric cancer organoids exhibit a high degree of pathological similarity to patient-derived tumor tissues, expressing key gastric cancer markers such as CK7, CEA, and LGR5. Immunohistochemistry (IHC) analyses confirm that these markers are expressed in the organoids in patterns consistent with those observed in primary tumors, accurately reflecting the differentiation status and histological characteristics of the original tissue.

These pathological marker analyses demonstrate that gastric cancer organoids faithfully recapitulate the morphological and molecular features of patient tumors, establishing them as a reliable platform for cancer pathology research, drug development, and the evaluation of personalized therapeutic strategies.

Cellular and structural similarity

The gastric cancer (GC) and ascites-derived organoid platform provides a physiologically relevant model that reflects the genetic characteristics of patient tumors.

Whole Exome Sequencing (WES) has been performed on the organoid library, identifying key driver mutations commonly found in gastric cancer.

These genomic profiles are visualized using Oncoplots, providing clear interpretation of the genetic features of each organoid model.

With WES data already established, cancer organoids harboring specific gene mutations can be selectively utilized for targeted drug testing, mechanistic studies, and mutation-driven drug response analysis.

These organoids serve as versatile models that reflect diverse tumor characteristics such as metastasis, treatment resistance, and drug sensitivity, making them effective for evaluating both standard therapies and novel anticancer strategies.

This platform supports mutation-specific organoid selection and testing, positioning it as a powerful tool for precision oncology and the development of personalized cancer therapies.

Drug sensitivity testing for Precision Oncology

A tailored solution for evaluating the efficacy and resistance of new drugs is available using an established gastric cancer organoid library.

By leveraging comprehensive drug sensitivity data, the most suitable organoid lines are selected based on the characteristics of the investigational drug, enabling precise and reliable drug testing.

Drug sensitivity tests have been conducted using Carboplatin and Cisplatin, Paclitaxel which are widely used in clinical gastric cancer treatment, and drug response data has been collected from a subset of gastric cancer organoid models, comprising over 16 distinct lines.

This dataset continues to expand as additional testing is performed.

This organoid-based drug sensitivity testing platform enhances the efficiency and reliability of the drug development process and contributes to the advancement of personalized cancer treatment strategies.

Connect with Us